Company Overview and News

Procter & Gamble Sinks, Now Worst-Performing Dow Stock of 2018

2018-04-21 247wallst
Consumer products maker Procter & Gamble Co. (NYSE: PG) saw nearly 6% of its share price shaved away last week. That was enough for the company to wrestle away from GE the dubious honor of being the worst-performing Dow Jones industrial average stock of the year so far. P&G’s stock has dropped 19.8% since 2018 began.
Upvote Downvote

Stock Market News For Apr 20, 2018

2018-04-20 zacks
U.S. stock markets ended in the red on Thursday with all three major indexes declined broadly. Thursday’s earnings results failed to live up to investor’s expectations despite remain strong. Moreover, a spike in the yield of 10-year Treasury Note also panicked investors. However, the markets shed some of its losses in the final hour of trading following as the news surfaced that President Trump is not the subject of Special Counsel Robert Mueller's investigation.
Upvote Downvote

Germany's Merck seeks partners for cancer and immune system drugs

2018-04-20 channelnewsasia
Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D.
Upvote Downvote

FOCUS-Germany's Merck seeks partners for cancer and immune system drugs

2018-04-20 reuters
FRANKFURT (Reuters) - Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D.
Upvote Downvote

Deals Buzz: P&G to acquire Merck India business for Rs1,300 crore

2018-04-20 livemint
Mint brings to you your daily dose of top deals reported by newsrooms across the country.
Upvote Downvote

P&G to buy Merck’s consumer health unit for US$4.2bil

The purchase gives it vitamin brands such as Seven Seas and greater exposure to Latin American and Asian markets.
Upvote Downvote

Merck's (MKGAF) CEO Stefan Oschmann on Procter & Gamble To Acquire Consumer Health Business - Call Transcript

2018-04-19 seekingalpha
Merck KGaA (OTCPK:MKGAF) Procter & Gamble To Acquire Consumer Health Business Conference Call April 19, 2018 6:00 AM ET
Upvote Downvote

Merck KGaA 2018 Q1 - Results - Earnings Call Slides

2018-04-19 seekingalpha
The following slide deck was published by Merck KGaA in conjunction with their 2018 Q1 earnings call.
Upvote Downvote

Procter & Gamble's (PG) CEO David Taylor on Q3 2018 Results - Earnings Call Transcript

2018-04-19 seekingalpha
The Procter & Gamble Company (NYSE:PG) Q3 2018 Results Conference Call April 19, 2018 8:30 AM ET
Upvote Downvote

P&G reports flat profit, plans to buy Merck unit

2018-04-19 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to:
Upvote Downvote

Juniper Pharmaceuticals: Undervalued With Double-Digit Revenue Growth

2018-04-19 seekingalpha
Juniper Pharmaceuticals licensed its leading revenue drug, Crinone, to Merck, with a fixed contract through 2024.
Upvote Downvote

Procter & Gamble (PG) To Acquire Consumer Health Business Of Merck KGaA - Slideshow

2018-04-19 seekingalpha
The following slide deck was published by The Procter & Gamble Company in conjunction with this event.
Upvote Downvote

P&G Acquires Merck KGaA’s Consumer Health Business, Pfizer Spurned Again

2018-04-19 biospace
Pfizer’s consumer health business has been spurned again. This time by mega-consumer goods company Proctor & Gamble. which opted today to acquire Germany-based Merck KGaA’s consumer health unit for $4.2 billion.
Upvote Downvote

Procter & Gamble (PG) Q3 Earnings Top Estimates, View Raised

2018-04-19 zacks
The Procter & Gamble Company (PG - Free Report) , popularly known as P&G, reported third-quarter fiscal 2018 financial results, wherein both earnings and revenues surpassed expectations, benefiting from higher demand for skincare products, along with fabric and home care products. The company has also lifted its core earnings per share guidance. P&G’s fiscal third-quarter core earnings of $1.00 per share beat the Zacks Consensus Estimate of 98 cents by 2%.
Upvote Downvote

Procter & Gamble Earnings and Acquisition Not Enough for Investors

2018-04-19 247wallst
Procter & Gamble Co. (NYSE: PG) made a couple big announcements on Thursday. First the firm released its fiscal third-quarter financial results, and then it announced an acquisition. Ultimately, these big moves by the Dow Jones industrial average component were met by investor remorse.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 589339100